EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Go back to EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD| (NASDAQ: EYPT) | Delayed: 3.85 -0.14 (3.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.99 | 52 Week High | $ | |||
| Open | $3.95 | 52 Week Low | $ | |||
| Day High | $4.06 | P/E | N/A | |||
| Day Low | $3.77 | EPS | $ | |||
| Volume | 7,264,455 | |||||
